Login to Your Account



Pharma: Other News To Note


Monday, July 30, 2012
• Mylan Inc., of Pittsburgh, reported that its subsidiary Mylan Pharmaceuticals Inc. received FDA approval for its generic version of Janssen Pharmaceutical Inc.'s Sporanox (itraconazole), indicated for the treatment of fungal infections that begin in the lungs in patients who are intolerant of or refractory to amphotericin B therapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription